Roche: Shionogi's anti-flu drug gets positive results

(CercleFinance.com) - Shionogi's baloxavir marboxil influenza treatment performed well in comparison with a placebo, potentially reducing complications and transmission of the virus to others.


On Friday the Japanese drugmaker released results of two phase II and III studies for the treatment of influenza in the New England Journal of Medicine.

In the Phase II study conducted in adults in Japan, the antiviral drug demonstrated a reduction in time to alleviation of symptoms compared with the placebo.

In the global Phase III study in patients of 12 years of age and older, baloxavir marboxil also reduced time to alleviation of symptoms compared with the placebo, the firm said.

In 2016 Shionogi entered into a license and collaboration agreement with Roche for the anti-flu drug, which was approved in Japan earlier this year.

Copyright (c) 2018 CercleFinance.com. All rights reserved.